Lichter Jay's Form 4 filing
Janux Therapeutics, Inc. (JANX) · filed Jun 5, 2024
- Accession no.
- 0001415889-24-015678
- Filed
- Jun 5, 2024
- Trade date
- Jun 3, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $82.1M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lichter JayCIK 0001376355 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 3, 2024 | Common Stock | SSaleDisposed | −677,279 | $54.75 | −$37,081,025.25 | 3,271,216 | Indirect | |
| Jun 3, 2024 | Common Stock | SSaleDisposed | −131,196 | $54.75 | −$7,182,981 | 633,673 | Indirect | |
| Jun 3, 2024 | Common Stock | SSaleDisposed | −691,525 | $54.75 | −$37,860,993.75 | 3,340,018 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.